The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...

A new FTC report found that pharmacy benefit managers have inflated the price of life-saving generic prescription drugs, ...

The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

Specifically, the FTC’s first report found Caremark, Express Scripts and Optum Rx were prioritizing access to high-cost drugs in return for larger discounts from drugmakers and giving their own ...

The FTC analyzed data for 51 specialty generic drugs dispensed from 2017-2022 for patients with commercial insurance or Medicare Part D plans managed by CVS Caremark, Express Scripts and OptumRx.

In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

“In contrast, branded specialty products represent more than 50% of our clients’ total drug spend and are entirely ignored by the FTC.” Express Scripts, meanwhile, declared in a statement th ...

FTC’s report focused on three largest PBMs: CVS Health Corporation’s CVS Caremark, The Cigna Group’s CI Express Scripts, and UnitedHealth Group Incorporated’s UNH Optum Rx. This report ...

the U.S. Federal Trade Commission said on Tuesday. From 2017 to 2022, the companies — UnitedHealth Group's UNH.N Optum, CVS Health's CVS.N CVS Caremark and Cigna's CI.N Express Scripts ...